Skip to main content
. Author manuscript; available in PMC: 2024 Oct 9.
Published in final edited form as: Cancer Cell. 2023 Sep 21;41(10):1803–1816.e8. doi: 10.1016/j.ccell.2023.08.013

Figure 5. ZNF683 marks a distinct population in RS and CLL with prognostic significance.

Figure 5.

(A) ZNF683 TPMs corrected for T cell content in RS bulk RNA-seq samples (N=35) (top). Top 20% of samples, blue; bottom 80%, pink.

(B) Cluster 1-ZNF683high signature and ZNF683 expression normalized for T cell content in bulk-RNA-seq data from 35 independent patients with RS (bottom).

(C) ZNF683 TPMs corrected for T cell content in CLL bulk-RNA-seq samples (n=81) (top). Top 20% of samples, blue; bottom 80%, yellow.

(D) Heatmap showing Z scores of single-sample GSEA scores for identified CD8+ T cell clusters as compared to Pancancer analysis CD8+ T cell clusters (Zheng et al., 2021).

(E) Survival curve showing ZNF683 expression and C1 gene expression signature with overall survival in PD-1 treated27 (top) and TCGA melanoma (bottom) data.